专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2012392187B2 Method of weight management 未知
公开(公告)号：AU2012392187B2
公开(公告)日：2018-07-12
申请号：AU2012392187
申请日：2012-11-06
申请人： ARENA PHARM INC , SANCHEZ MATILDE , SHANAHAN WILLIAM R
发明人： SANCHEZ MATILDE , SHANAHAN WILLIAM R
IPC分类号： A61K31/55 , A61P3/04
摘要： Provided are methods of determining if an individual is a responder to treatment with (

2. 发明申请

WO2012030939A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT 审中-公开
标题翻译： LORCASERIN对具有肾功能不全的个体的管理
公开(公告)号：WO2012030939A1
公开(公告)日：2012-03-08
申请号：PCT/US2011/049936
申请日：2011-08-31
申请人： ARENA PHARMACEUTICALS, INC. , ANDERSON, Christen M. , SHANAHAN, William R.
发明人： ANDERSON, Christen M. , SHANAHAN, William R.
IPC分类号： A61K31/55 , A61P3/04
CPC分类号： A61K31/55 , A61K9/0053 , G01N33/70 , Y10T436/147777
摘要： The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.
摘要翻译：本公开内容涉及通过确定个体的肾功能水平并开出或施用治疗有效量的（R）-8-氯-1-甲基-2,3,5-三唑并[ 4,5-四氢-1H-3-苯并吖庚因或其药学上可接受的盐，溶剂合物或水合物，条件是个体具有选自以下的肾功能水平：无肾损伤，轻度肾损伤，和中度肾损伤。此外，本公开涉及用（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂或其药学上可接受的盐，溶剂化物或水合物从多个需要体重管理的个体中确定个体的肾功能水平，并选择个体用（R）-8-氯-1-甲基-2,3,4,5-四氢 - 四氢-1H-3-苯并吖庚因或其药学上可接受的盐，溶剂化物或水合物，如果个体具有选自以下的肾功能水平：无肾损伤，轻度肾损伤和中度肾损伤。

3. 发明申请

WO2004052309A2 MODULATION OF STAT 6 EXPRESSION 审中-公开
标题翻译： STAT 6表达调控
公开(公告)号：WO2004052309A2
公开(公告)日：2004-06-24
申请号：PCT/US2003/039492
申请日：2003-12-11
申请人： ISIS PHARMACEUTICALS, INC. , SHANAHAN, William, R. , FREIER, Susan, M. , DOBIE, Kenneth, W.
发明人： SHANAHAN, William, R. , FREIER, Susan, M. , DOBIE, Kenneth, W.
IPC分类号： A61K
CPC分类号： C12N15/113 , C07H21/04 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Q1/6886 , C12Q2600/136 , C12Q2600/16 , C12N2310/3525
摘要： Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.
摘要翻译：提供化合物，组合物和方法用于调节STAT6的表达。组合物包含靶向编码STAT6的核酸的寡核苷酸。使用这些化合物调节STAT6表达并用于诊断和治疗与表达相关的疾病提供STAT 6。

4. 发明申请

WO2012030953A1 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL 审中-公开
标题翻译： 5-HT2C受体拮抗剂通过降低肾上腺素水平来治疗疾病
公开(公告)号：WO2012030953A1
公开(公告)日：2012-03-08
申请号：PCT/US2011/049955
申请日：2011-08-31
申请人： ARENA PHARMACEUTICALS, INC. , ANDERSON, Christen, M. , SHANAHAN, William, R.
发明人： ANDERSON, Christen, M. , SHANAHAN, William, R.
IPC分类号： A61K31/00 , A61K31/55
CPC分类号： A61K31/55 , A61K31/00
摘要： Uses of 5-HT 2C receptor agonists in the treatment of disorders ameliorated by reduction of an individual's norepinephrine level, wherein said disorders include but are not limited to hypernorepinephrinemia, cardiomyopathy, cardiac hypertrophy, cardiomyocyte hypertrophy in post-myocardial infarction remodeling, elevated heart rate, vasoconstriction, acute pulmonary vasoconstriction, hypertension, heart failure, cardiac dysfunction after stroke, cardiac arrhythmia, metabolic syndrome, abnormal lipid metabolism, hyperthermia, Cushing syndrome, pheochromocytoma, epilepsy, obstructive sleep apnea, insomnia, glaucoma, osteoarthritis, rheumatoid arthritis, and asthma.
摘要翻译： 5-HT 2C受体激动剂在治疗通过减少个体去甲肾上腺素水平而改善的病症中的用途，其中所述疾病包括但不限于高肾上腺素肾血症，心肌病，心脏肥大，心肌梗塞后心肌重塑中的心肌细胞肥大，心率升高，血管收缩，急性肺血管收缩，高血压，心力衰竭，卒中后心脏功能障碍，心律失常，代谢综合征，脂代谢异常，高热，库兴综合征，嗜铬细胞瘤，癫痫，阻塞性睡眠呼吸暂停，失眠，青光眼，骨关节炎，类风湿性关节炎和哮喘。

5. 发明申请

WO2004052309A3 MODULATION OF STAT 6 EXPRESSION 审中-公开
标题翻译： STAT 6表达调控
公开(公告)号：WO2004052309A3
公开(公告)日：2005-04-28
申请号：PCT/US0339492
申请日：2003-12-11
申请人： ISIS PHARMACEUTICALS INC , SHANAHAN WILLIAM R , FREIER SUSAN M , DOBIE KENNETH W
发明人： SHANAHAN WILLIAM R , FREIER SUSAN M , DOBIE KENNETH W
IPC分类号： C07H21/04 , C12N15/113 , C12Q1/68 , A01N43/04 , A61K31/70 , C12N5/00
CPC分类号： C12N15/113 , C07H21/04 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Q1/6886 , C12Q2600/136 , C12Q2600/16 , C12N2310/3525
摘要： Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.
摘要翻译：提供化合物，组合物和方法用于调节STAT6的表达。组合物包含靶向编码STAT6的核酸的寡核苷酸。使用这些化合物调节STAT6表达并用于诊断和治疗与表达相关的疾病提供STAT 6。

6. 发明申请

WO2014058441A1 METHOD OF WEIGHT MANAGEMENT 审中-公开
标题翻译：权重管理方法
公开(公告)号：WO2014058441A1
公开(公告)日：2014-04-17
申请号：PCT/US2012/063711
申请日：2012-11-06
申请人： ARENA PHARMACEUTICALS, INC. , SANCHEZ, Matilde , SHANAHAN, William R.
发明人： SANCHEZ, Matilde , SHANAHAN, William R.
IPC分类号： A61K31/55 , A61P3/04
CPC分类号： A61K31/55 , A23L33/30 , A23V2002/00 , A61B5/0073 , A61B5/0537 , A61B5/055 , A61B5/107 , A61B5/4848 , A61B5/4869 , A61B5/4872 , A61B6/03 , A61B6/482 , A61B6/50 , A61B8/48 , A61K9/0053 , A61K9/20 , A61K31/137 , A61K45/06 , A61K49/0004 , A63B24/0075 , C07D223/16 , G09B19/003 , G09B19/0092 , A61K2300/00
摘要： Provided are methods of determining if an individual is a responder to treatment with ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
摘要翻译：提供了确定个体是否是用（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂或其药学上可接受的盐，溶剂合物或水合物处理的应答者的方法它们。还提供了选择个体用（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂或其药学上可接受的盐，溶剂合物或水合物从多个人需要体重管理。还提供了有需要的个体中的体重管理方法。还提供了用于个体体重管理方法的化合物，组合物和试剂盒。

7. 发明专利

CA2886875A1 METHOD OF WEIGHT MANAGEMENT 未知
公开(公告)号：CA2886875A1
公开(公告)日：2014-04-17
申请号：CA2886875
申请日：2012-11-06
申请人： ARENA PHARM INC , SANCHEZ MATILDE , SHANAHAN WILLIAM R
发明人： SANCHEZ MATILDE , SHANAHAN WILLIAM R
IPC分类号： A61K31/55 , A61P3/04
摘要： Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式